Foralumab

Drug Profile

Foralumab

Alternative Names: NI-0401; NI-0401/α-CD3

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Medarex; NovImmune SA
  • Developer NovImmune SA; Tiziana Life Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Discontinued Crohn's disease; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 05 Jan 2017 Discontinued - Phase-II for Crohn's disease in European Union (IV)
  • 05 Jan 2017 Discontinued - Phase-II for Transplant rejection (Prevention) in European Union (IV)
  • 05 Jan 2017 Preclinical trials in Inflammatory bowel disease in United Kingdom (Parenteral) before January 2017 (Tiziana company pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top